![Follow-Up Results From Study Comparing SPRYCEL(R) (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML Demonstrate Improved Response Rates Consistent With 12 Month Data[1]](https://www.science20.com/graphics/defimages/.jpg "Follow-Up Results From Study Comparing SPRYCEL(R) (dasatinib) To Imatinib In First-Line Treatment Of Adults With Ph+ CP-CML Demonstrate Improved Response Rates Consistent With 12 Month Data[1]")
Know Science And Want To Write?
Apply for a column: writing@science20.com
Donate or Buy SWAG
Please donate so science experts can write
for the public.
At Science 2.0, scientists are the journalists,
with no political bias or editorial control. We
can't do it alone so please make a difference.
We are a nonprofit science journalism
group operating under Section 501(c)(3)
of the Internal Revenue Code that's
educated over 300 million people.
You can help with a tax-deductible
donation today and 100 percent of your
gift will go toward our programs,
no salaries or offices.
Interesting insights from outside Science 2.0
